founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Company profile
Ticker
ARCT
Exchange
Website
CEO
Joseph E. Payne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ARCT stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
5 Apr 24
8-K
Regulation FD Disclosure
19 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K/A
Results of Operations and Financial Condition
14 Mar 24
8-K
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
7 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
26 Sep 23
8-K
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
14 Aug 23
Transcripts
ARCT
Earnings call transcript
2023 Q4
7 Mar 24
ARCT
Earnings call transcript
2023 Q3
14 Nov 23
ARCT
Earnings call transcript
2023 Q2
7 Aug 23
ARCT
Earnings call transcript
2023 Q1
9 May 23
ARCT
Earnings call transcript
2022 Q4
28 Mar 23
ARCT
Earnings call transcript
2022 Q3
10 Nov 22
ARCT
Earnings call transcript
2022 Q2
10 Aug 22
ARCT
Earnings call transcript
2022 Q1
10 May 22
ARCT
Earnings call transcript
2021 Q4
1 Mar 22
ARCT
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
SC 13G/A
BlackRock Inc.
5 Apr 24
4
Pad Chivukula
27 Mar 24
4
Pad Chivukula
21 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Nikko Asset Management Americas, Inc.
12 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 369.05 mm | 369.05 mm | 369.05 mm | 369.05 mm | 369.05 mm | 369.05 mm |
Cash burn (monthly) | 3.85 mm | (no burn) | 6.44 mm | (no burn) | 10.80 mm | (no burn) |
Cash used (since last report) | 26.14 mm | n/a | 43.72 mm | n/a | 73.35 mm | n/a |
Cash remaining | 342.91 mm | n/a | 325.33 mm | n/a | 295.70 mm | n/a |
Runway (months of cash) | 89.1 | n/a | 50.5 | n/a | 27.4 | n/a |
Institutional ownership, Q3 2019
17.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 21 |
Closed positions | 2 |
Increased positions | 14 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 47.34 mm |
Total shares | 4.61 mm |
Total puts | 55.04 k |
Total calls | 34.43 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 1.27 mm | $13.09 mm |
DFPG Investments | 460.45 k | $4.80 mm |
Townsquare Capital | 451.55 k | $4.54 mm |
FMR | 400.00 k | $4.11 mm |
Nikko Asset Management Americas | 298.53 k | $3.07 mm |
CMTDF Sumitomo Mitsui Trust | 298.53 k | $3.07 mm |
DAFNA Capital Management | 173.91 k | $1.79 mm |
Sabby Management | 124.84 k | $1.28 mm |
Vanguard | 123.88 k | $1.27 mm |
Royce & Associates | 106.44 k | $1.09 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Chivukula Pad | Common Stock | Sell | Dispose S | No | Yes | 35.02 | 17,435 | 610.57 k | 473,448 |
19 Mar 24 | Chivukula Pad | Common Stock | Sell | Dispose S | No | Yes | 35.0075 | 8,565 | 299.84 k | 490,883 |
15 Dec 23 | Payne Joseph E | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 28.88 | 200,000 | 5.78 mm | 200,000 |
15 Dec 23 | Chivukula Pad | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 28.88 | 125,000 | 3.61 mm | 125,000 |
15 Dec 23 | Lance Kurata | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 28.88 | 75,000 | 2.17 mm | 75,000 |
News
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
11 Mar 24
Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87
11 Mar 24
HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
8 Mar 24
Recap: Arcturus Therapeutics Q4 Earnings
7 Mar 24
Arcturus Therapeutics Q4 2023 GAAP EPS $(0.320) Beats $(0.760) Estimate, Sales $33.989M Miss $37.856M Estimate
7 Mar 24
Press releases
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
7 Mar 24
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
26 Feb 24
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
22 Feb 24
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
5 Feb 24